Key PointsWhen evaluating the two companies based strictly on the most recent quarterly data, Eli Lilly currently shows a higher overall revenue base and a demonstrably faster upward sales trajectory than Bristol Myers Squibb.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.